BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 23924003)

  • 1. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
    Vander Lugt MT; Braun TM; Hanash S; Ritz J; Ho VT; Antin JH; Zhang Q; Wong CH; Wang H; Chin A; Gomez A; Harris AC; Levine JE; Choi SW; Couriel D; Reddy P; Ferrara JL; Paczesny S
    N Engl J Med; 2013 Aug; 369(6):529-39. PubMed ID: 23924003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
    Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
    Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
    Matsumura A; Miyazaki T; Tachibana T; Ando T; Koyama M; Koyama S; Ishii Y; Takahashi H; Nakajima Y; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S; Nakajima H
    Turk J Haematol; 2020 Feb; 37(1):20-29. PubMed ID: 31464120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Aladağ Karakulak E; Demİroğlu H; Malkan UY; Akman U; Göker H; Büyükaşik Y
    Turk J Med Sci; 2021 Feb; 51(1):355-358. PubMed ID: 32927932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide.
    Solán L; Kwon M; Carbonell D; Dorado N; Balsalobre P; Serrano D; Chicano-Lavilla M; Anguita J; Gayoso J; Díez-Martín JL; Martínez-Laperche C; Buño I
    Front Immunol; 2019; 10():2338. PubMed ID: 31649665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD.
    Reichenbach DK; Schwarze V; Matta BM; Tkachev V; Lieberknecht E; Liu Q; Koehn BH; Pfeifer D; Taylor PA; Prinz G; Dierbach H; Stickel N; Beck Y; Warncke M; Junt T; Schmitt-Graeff A; Nakae S; Follo M; Wertheimer T; Schwab L; Devlin J; Watkins SC; Duyster J; Ferrara JL; Turnquist HR; Zeiser R; Blazar BR
    Blood; 2015 May; 125(20):3183-92. PubMed ID: 25814531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
    Levine JE; Braun TM; Harris AC; Holler E; Taylor A; Miller H; Magenau J; Weisdorf DJ; Ho VT; Bolaños-Meade J; Alousi AM; Ferrara JL;
    Lancet Haematol; 2015 Jan; 2(1):e21-9. PubMed ID: 26687425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.
    Ponce DM; Hilden P; Mumaw C; Devlin SM; Lubin M; Giralt S; Goldberg JD; Hanash A; Hsu K; Jenq R; Perales MA; Sauter C; van den Brink MR; Young JW; Brentjens R; Kernan NA; Prockop SE; O'Reilly RJ; Scaradavou A; Paczesny S; Barker JN
    Blood; 2015 Jan; 125(1):199-205. PubMed ID: 25377785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD.
    Etra A; El Jurdi N; Katsivelos N; Kwon D; Gergoudis S; Morales G; Spyrou N; Kowalyk S; Aguayo-Hiraldo P; Akahoshi Y; Ayuk F; Baez J; Betts BC; Chanswangphuwana C; Chen YB; Choe H; DeFilipp Z; Gleich S; Hexner E; Hogan WJ; Holler E; Kitko CL; Kraus S; Al Malki M; MacMillan M; Pawarode A; Quagliarella F; Qayed M; Reshef R; Schechter T; Vasova I; Weisdorf D; Wölfl M; Young R; Nakamura R; Ferrara JLM; Levine JE; Holtan S
    Blood Adv; 2024 Jun; 8(12):3284-3292. PubMed ID: 38640195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival.
    Kordelas L; Buttkereit U; Heinemann FM; Horn PA; Giebel B; Beelen DW; Reinhardt HC; Rebmann V
    Front Immunol; 2021; 12():694843. PubMed ID: 34630383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups.
    Rowan CM; Pike F; Cooke KR; Krance R; Carpenter PA; Duncan C; Jacobsohn DA; Bollard CM; Cruz CRY; Malatpure A; Farag SS; Renbarger J; Liu H; Bakoyannis G; Hanash S; Paczesny S
    Blood; 2020 Apr; 135(17):1428-1437. PubMed ID: 31972009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation.
    Gjaerde LK; Ostrowski SR; Minculescu L; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
    Eur J Haematol; 2021 Mar; 106(3):417-424. PubMed ID: 33314420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment.
    McDonald GB; Tabellini L; Storer BE; Lawler RL; Martin PJ; Hansen JA
    Blood; 2015 Jul; 126(1):113-20. PubMed ID: 25987657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.
    Qayed M; Kapoor U; Gillespie S; Westbrook A; Aguayo-Hiraldo P; Ayuk FA; Aziz M; Baez J; Choe H; DeFilipp Z; Etra A; Grupp SA; Hexner E; Holler E; Hogan WJ; Kowalyk S; Merli P; Morales G; Nakamura R; Pulsipher MA; Schechter T; Shah J; Spyrou N; Srinagesh HK; Wölfl M; Yanik G; Young R; Kitko CL; Ferrara JLM; Levine JE
    Transplant Cell Ther; 2024 Jun; 30(6):603.e1-603.e11. PubMed ID: 38548227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in protein serum levels during stem cell transplantation.
    Metafuni E; Giammarco S; De Ritis DG; Rossi M; Corrente F; Piccirillo N; Bacigalupo AP; Sica S; Chiusolo P
    Eur J Clin Invest; 2017 Oct; 47(10):711-718. PubMed ID: 28796281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.
    McDonald GB; Tabellini L; Storer BE; Martin PJ; Lawler RL; Rosinski SL; Schoch HG; Hansen JA
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1257-1263. PubMed ID: 28478120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
    Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
    Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
    Hartwell MJ; Özbek U; Holler E; Renteria AS; Major-Monfried H; Reddy P; Aziz M; Hogan WJ; Ayuk F; Efebera YA; Hexner EO; Bunworasate U; Qayed M; Ordemann R; Wölfl M; Mielke S; Pawarode A; Chen YB; Devine S; Harris AC; Jagasia M; Kitko CL; Litzow MR; Kröger N; Locatelli F; Morales G; Nakamura R; Reshef R; Rösler W; Weber D; Wudhikarn K; Yanik GA; Levine JE; Ferrara JL
    JCI Insight; 2017 Feb; 2(3):e89798. PubMed ID: 28194439
    [No Abstract]   [Full Text] [Related]  

  • 20. Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.
    Farag SS; Abu Zaid M; Schwartz JE; Thakrar TC; Blakley AJ; Abonour R; Robertson MJ; Broxmeyer HE; Zhang S
    N Engl J Med; 2021 Jan; 384(1):11-19. PubMed ID: 33406328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.